A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Olaparib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use

11 Oct 2024 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
11 Oct 2024 Planned primary completion date changed from 30 Jul 2024 to 30 Jul 2025.
04 Jun 2024 Results (n=19) of the expansion cohorts for additional pts with gPALB2(Cohort 1a) or sBRCA (Cohort 2a) mutations, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com